Site Search
Professionals 646 results
Capabilities 81 results
Industry
The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative healthcare landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Healthcare & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions.
Industry
Winston’s financial crimes compliance lawyers have been providing regulatory compliance counseling and enforcement services related to the Bank Secrecy Act (BSA), the Anti-Money Laundering Act of 2020 (AML), and countering the financing of terrorism (CFT) policy for decades. We also have experience with international AML matters, including in the EU and with respect to Financial Actions Task Force (FATF) recommendations.
Industry
Experience 166 results
Experience
|November 26, 2025
Winston & Strawn Represented CFS Brands in its Acquisition of Cornerstone Foodservice Group
Winston represented CFS Brands, a portfolio company of TJC, in its acquisition of Cornerstone Foodservice Group, a global leader in foodservice equipment serving both front- and back-of-house applications through a portfolio of established, innovative brands.
Experience
|October 27, 2025
Winston Advised GenNx360 Capital Partners in its Completed Sale of Aero 3, Inc. to VSE Corporation
On Tuesday, December 23, VSE Corporation, a leading provider of aviation aftermarket distribution and repair services, completed its previously announced acquisition of Aero 3 Inc., a diversified global maintenance, repair, and overhaul service provider, from GenNx360 Capital Partners.
Experience
|October 1, 2025
AA Mission Acquisition Corp. II - Initial Public Offering
Winston & Strawn LLP represented AA Mission Acquisition Corp. II, a blank check company, in the recent closing of its $100 million Initial Public Offering (IPO). The offering consisted of 10,000,000 units priced at $10.00 per unit, before deducting underwriting discounts and estimated offering expenses. The units began trading on the New York Stock Exchange (NYSE) under the ticker symbol “YCY.U” on October 1, 2025.
Insights & News 5,894 results
Seminar/CLE
|January 20, 2026
Winston & Strawn and RSM US LLP are co-hosting the annual NYC SBIC Fund Conference on Tuesday, January 20, 2026.General and limited partners, chief financial officers, and controllers of small business investment company (SBIC) funds are invited to a half-day seminar covering various topics related to SBIC fund operations, including:
Recognitions
|January 9, 2026
|1 Min Read
Winston & Strawn’s Antitrust/Competition Practice Honored in 2026 GCR 100
Global Competition Review has recognized Winston & Strawn’s Antitrust/Competition Practice as “highly recommended” in New York, Illinois, and California in the 2026 GCR 100. For over two decades, GCR 100 has provided a comprehensive list of the world’s best competition practices based on a quantitative and qualitative analysis of the law firms and economic consultancies doing the most important antitrust work around the world.
Recognitions
|January 9, 2026
|Less Than 1 Min Read
Winston Recognized in World Intellectual Property Review’s 2025 Trademark Rankings
Winston was recognized in World Intellectual Property Review's (WIPR) USA Trademark Rankings 2025. The rankings are “designed to identify the foremost legal talent dedicated to brand protection across the US.”
Other Results 88 results
Law Glossary
What Is the Standard for the FDA to Grant a Generic Drug License?
An Abbreviated New Drug Application (ANDA) must contain evidence that the proposed generic drug product is bioequivalent to the reference drug.
Law Glossary
What Is the Approval Process for Generic Drugs?
Approval for generic drugs are governed by the Hatch-Waxman Act. The Hatch-Waxman Act provides the framework for an applicant to demonstrate that its proposed generic product is bioequivalent to the brand-name drug.
Law Glossary
Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—a typical small molecule drug—has a molecular weight of 180 daltons.